From Our Archives

Reports From National Arthritis Meeting 2004

Perspectives of Interest On Arthritis Drugs & New Medications From
2004 Annual Scientific Meeting Of The American College of Rheumatology.


Scientists throughout the world are studying many promising areas of new treatment approaches for arthritis and rheumatic diseases. These areas include monoclonal antibody therapy that is directed against a special inflammation factor called the tumor necrosis factor (TNFalpha) (as described below regarding Remicade and Enbrel), and new TNF human antibodies (see Humira below). Also, new non-steroidal antiinflammatory drugs (NSAIDs), with mechanisms of action that are different from current drugs, are on the horizon. There was interesting discussion about the arthritis drug Vioxx that was removed from the market on September 30, 2004 because of risks of heart attack and stroke (see below).Genetic research and engineering are also likely to bring forth many new avenues of earlier diagnosis and treatment in the near future.

Medically Reviewed by a Doctor on 9/16/2015

Health Solutions From Our Sponsors